RPG Life Sciences · NSE: RPGLIFE · BSE: 532983
Q2 FY20 results · Jul–Sep 2019
RPG Life Sciences reported revenue from operations of ₹98.49 crore (up 8.8% from Q2 FY19) and net profit of ₹9.77 crore (up 352.3% from Q2 FY19) for Q2 FY20 (Jul–Sep 2019), on a standalone basis.
| Item | Q2 FY20 | Q2 FY19 | YoY | Q1 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 98.49 | 90.50 | +8.8% | 94.04 | +4.7% |
| Other income | 0.15 | 0.06 | +150.0% | 0.16 | −6.2% |
| Total income | 98.64 | 90.56 | +8.9% | 94.20 | +4.7% |
| Profit before tax | 12.04 | 3.10 | +288.4% | 10.86 | +10.9% |
| Net profit for the period | 9.77 | 2.16 | +352.3% | 8.35 | +17.0% |
| EPS, basic (₹) | 5.91 | 1.31 | +351.1% | 5.05 | +17.0% |
| Net margin (%) | 9.9 | 2.4 | 8.9 |
Standalone
- Filed with BSE
- 31 Oct 2019, 18:16 IST
- Board meeting
- 30 Oct 2019
- Period
- 01 Jul 2019 to 30 Sep 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE